- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Propanc Biopharma, Inc.: Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib | 207 | GlobeNewswire (Europe) | MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| PROPANC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 05.10. | Propanc Biopharma, Inc. - S-1, General form for registration of securities | 4 | SEC Filings | ||
| 29.09. | Propanc Biopharma, Inc. GAAP EPS of -$17.62 | 2 | Seeking Alpha | ||
| 29.09. | Propanc Biopharma reports $18.9M loss, plans phase 1b trial | 4 | Investing.com | ||
| 29.09. | Propanc Biopharma, Inc.: Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results | 240 | GlobeNewswire (Europe) | MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 25.09. | Propanc Biopharma, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 22.09. | Propanc Biopharma, Inc.: Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 | 4 | GlobeNewswire (USA) | ||
| 16.09. | Propanc Biopharma, Inc.: Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | 6 | GlobeNewswire (USA) | ||
| 09.09. | Propanc Biopharma plans phase 1b cancer trial in Australia | 4 | Investing.com | ||
| 09.09. | Propanc Biopharma, Inc.: Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 | 729 | GlobeNewswire (Europe) | MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 27.08. | Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results | 5 | Benzinga.com | ||
| 27.08. | Propanc Biopharma, Inc.: Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit | 417 | GlobeNewswire (Europe) | MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 18.08. | Propanc Biopharma, Inc.: Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP | 261 | GlobeNewswire (Europe) | MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 12.08. | Propanc Biopharma, Inc.: Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers | 365 | GlobeNewswire (Europe) | MELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 06.08. | Propanc reports preclinical data for pancreatic cancer drug | 3 | Investing.com | ||
| 06.08. | Propanc meldet vielversprechende präklinische Daten für Medikament gegen Bauchspeicheldrüsenkrebs | 13 | Investing.com Deutsch | ||
| 06.08. | Propanc Biopharma, Inc.: Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models | 298 | GlobeNewswire (Europe) | MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| 05.08. | Propanc Biopharma, Inc.: Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program | 2 | GlobeNewswire (USA) | ||
| 21.07. | Propanc publishes research on recombinant enzyme production | 4 | Investing.com | ||
| 21.07. | Propanc Biopharma veröffentlicht Studie zur Produktion rekombinanter Enzyme | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,444 | -0,65 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| QIAGEN | 40,500 | -0,09 % | QIAGEN N.V.: QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery | New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results New QIAGEN Discovery Platform extends AI into drug... ► Artikel lesen | |
| AMGEN | 371,00 | -0,89 % | Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? | ||
| BIOFRONTERA | 3,050 | +4,10 % | Biofrontera AG: Was die neuen Zahlen jetzt enthüllen | ||
| CRISPR THERAPEUTICS | 44,815 | -3,02 % | Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. | ||
| BIONXT SOLUTIONS | 0,197 | -5,53 % | BioNxt, CrowdStrike und Shell: Drei spannende Aktien vor dem nächsten Kursschub | An der Börse zählen vor allem Fakten. So sorgen etwa neue Studienergebnisse, gute Zahlen und operative Rekorde bei Anlegern für erhöhtes Interesse und führen nicht selten auch zu steigenden Kursen.... ► Artikel lesen | |
| TEMPUS AI | 60,65 | -0,54 % | Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? | ||
| NOVONESIS | 59,28 | +1,47 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| GENMAB | 331,00 | -1,63 % | Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year | NEW BRUNSWICK (dpa-AFX) - Genmab (GMAB) announced that worldwide net sales of DARZALEX (daratumumab), as reported by partner Johnson & Johnson (JNJ), totaled $4.24 billion during the third quarter... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,243 | +0,83 % | Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates | Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| IMMUNITYBIO | 8,870 | -2,21 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TME PHARMA | 0,110 | 0,00 % | TME Pharma NV: TME Pharma CEO Message | TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,920 | -2,24 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| CYTODYN | 0,170 | 0,00 % | CytoDyn Inc.: CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 | ||
| IMMUNIC | 6,454 | -9,73 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen |
Das Unternehmen PROPANC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,430 Euro und damit -2,27 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROPANC BIOPHARMA INC finden Sie auf Wallstreet Online.